免疫療法用治療薬の世界市場：単クローン抗体、インターフェロンα、インターロイキン、ワクチン、チェックポイント阻害薬...市場調査レポートについてご紹介

1 Introduction (Page No. – 13)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 16)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.2.1 Key Data From Secondary Sources
2.2.2 Key Data From Primary Sources
2.2.2.1 Key Industry Insights
2.2.3 Assumptions for the Study

3 Executive Summary (Page No. – 23)

4 Premium Insights (Page No. – 26)
4.1 Immunotherapy Drugs Market to Grow at A Rapid Rate
4.2 Global Immunotherapy Drugs Market Size
4.3 Geographical Snapshot of the Immunotherapy Drugs Market
4.4 Immunotherapy Drugs Market, By Type of Drug
4.5 Lifecycle Analysis, By Region

5 Market Overview (Page No. – 30)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.4 Drivers
5.4.1 Increasing Adoption of Targeted Therapy Over Traditional Therapy
5.4.2 Reduction in Overall Timeline and Cost for Drug Discovery
5.4.3 High Prevalence Rate of Lifestyle Diseases
5.4.4 Fast Track and Orphan Drug Designations
5.5 Restraints
5.5.1 High Cost of Immunotherapy Treatment
5.5.2 High Attrition Rate in the Product Development Cycle
5.6 Opportunities
5.6.1 Significant Growth Prospects in Developing Countries
5.6.2 Immunotherapy to Replace Chemotherapy as A First-Line Therapy
5.7 Challenges
5.7.1 Patent Expiries of Top-Selling Biologics

6 Cancer Immunotherapy Market- Industry Insights (Page No. – 36)
6.1 Cancer Epidemiology
6.1.1 Estimated Incidence, Mortality, and 5-Year Prevalence: Men (2012)
6.1.2 Estimated Incidence, Mortality, and 5-Year Prevalence: Women
6.1.3 Estimated Incidence, Mortality, and 5-Year Prevalence: Both Sexes (2012)
6.2 Pricing and Reimbursement
6.2.1 U.S.
6.2.2 U.K.
6.2.3 France
6.2.4 Germany
6.2.5 Other European Countries
6.2.6 Japan
6.3 Pipeline
6.3.1 Phase 1
6.3.2 Phase I/II
6.3.3 Phase II
6.3.4 Phase II/III
6.3.5 Phase III
6.3.6 Application Submitted
6.4 Promising Molecules
6.5 Treatment Protocols and Line of Therapies
6.5.1 First Line Therapy
6.5.2 Second Line Therapy
6.5.3 Other Treatments

7 Immunotherapy Drugs Market, By Type of Drugs (Page No. – 63)
7.1 Introduction
7.2 Monoclonal Antibodies
7.3 Interferons
7.4 Interleukins
7.5 Vaccines
7.6 Checkpoint Inhibitors

8 Global Immunotherapy Drugs Market, By Region (Page No. – 76)
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.5 Rest of the World (RoW)

9 Competitive Landscape (Page No. – 94)
9.1 Overview
9.2 Market Share Analysis
9.3 Competitive Situation and Trends
9.3.1 Approvals
9.3.2 Agreements, Partnerships, and Collaborations
9.3.3 Acqusitions

10 Company Profiles (Page No. – 100)
10.1 Introduction
10.2 F. Hoffmann-La Roche Ag
10.2.1 Business Overview
10.2.2 F. Hoffmann-La Roche Ag: Company Snapshot
10.2.3 Products Offered
10.2.4 Recent Developments
10.2.5 MnM View
10.3 Merck & Co., Inc.
10.3.1 Business Overview
10.3.2 Merck & Co., Inc.: Company Snapshot
10.3.3 Products Offered
10.3.4 Recent Developmen
10.3.5 MnM View
10.4 Novartis International Ag
10.4.1 Business Overview
10.4.2 Novartis International Ag: Company Snapshot
10.4.3 Products Offered
10.4.4 Recent Developments
10.4.5 MnM View
10.5 Glaxosmithkline Plc
10.5.1 Business Overview
10.5.2 Glaxosmithkline Plc: Company Snapshot
10.5.3 Product Offered
10.5.4 Recent Developments
10.5.5 MnM View
10.6 Amgen Inc.
10.6.1 Business Overview
10.6.2 Amgen Inc.: Company Snapshot
10.6.3 Products Offered
10.6.4 Recent Developments
10.6.5 MnM View
10.7 Bristol-Myers Squibb
10.7.1 Business Overview
10.7.2 Bristol-Myers Squibb: Company Snapshot
10.7.3 Products Offered
10.7.4 Recent Developments
10.8 ELI Lilly and Company
10.8.1 Business Overview
10.8.2 ELI Lilly and Company: Company Snapshot
10.8.3 Product Offered
10.8.4 Recent Developments
10.9 Celgene Corporation
10.9.1 Business Overview
10.9.2 Celgene Corporation: Company Snapshot
10.9.3 Products Offered
10.9.4 Recent Development
10.10 Seattle Genetics, Inc.
10.10.1 Business Overview
10.10.2 Seattle Genetics, Inc.: Company Snapshot
10.10.3 Product Offered
10.10.4 Recent Developments
10.11 Spectrum Pharmaceuticals, Inc.
10.11.1 Business Overview
10.11.2 Spectrum Phrmaceuticals, Inc.: Company Snapshot
10.11.3 Product Offered
10.11.4 Recent Developments

11 Appendix (Page No. – 121)
11.1 Insights of Industry Experts
11.2 Discussion Guide
11.3 Introducing RT: Real-Time Market Intelligence
11.4 Available Customizations
11.5 Related Reports